Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. - Test2 - elhamkhani - TriplyDB

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

http://www.wikidata.org/entity/Q27853093

about

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine PI3K/Akt/mTOR inhibitors in breast cancer PI3K isoform-selective inhibitors: next-generation targeted cancer therapies The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients Targeting the adaptive molecular landscape of castration-resistant prostate cancer CIViC database Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy Implementing Genome-Driven Oncology.A Strategy to Delay the Development of Cisplatin Resistance by Maintaining a Certain Amount of Cisplatin-Sensitive Cells.PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3.Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.Hiding in the dark: uncovering cancer drivers through image-guided genomics.PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.Personalized targeted therapy for esophageal squamous cell carcinoma.APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.AKT signaling in ERBB2-amplified breast cancer.Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment.SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers.The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.Molecular profiling of head and neck squamous cell carcinoma.Quantification of nucleic acid quality in postmortem tissues from a cancer research autopsy program.Chromosomal Instability and Phosphoinositide Pathway Gene Signatures in Glioblastoma Multiforme Molecular pathogenesis of ovarian clear cell carcinoma.

P2860

Q26767415-7956AC71-32AB-4D80-839C-9E925E2A898B Q26771394-B1DB85FD-C017-43CD-836E-3F65E763155C Q26781294-131E352F-03DE-48EA-826D-CE52E9076D26 Q26782449-D6D5B2FE-B853-42CE-B25E-526874CD19AD Q27022821-BD773355-26CD-40D7-AAE1-752388E322D2 Q27612411-5CA327E9-2A71-4F01-A220-6F40ED6B8D5F Q27853245-509676BF-872C-491C-9282-7A895DDA2012 Q28118735-86B8D84F-E24F-41D4-9B11-A2C7E6B421C2 Q28602310-FDE73F47-1AD2-4CFB-AB1B-42A14ED86C35 Q29248893-DD5C7F73-A311-4E75-A2B9-86101610720B Q30235979-2B5817CF-3388-4329-8932-F3061F64B0B7 Q33671792-1308924B-0CE0-48D8-BB5B-9D6EC62FE31F Q33705644-0FA748C3-2935-40AC-98DD-D13DE18D85B1 Q33810500-ACFFA9D6-3297-47F0-8D2F-10EF45205C2C Q34554022-427476DE-4C28-4631-BBDF-011329434462 Q35030274-00343DE0-0724-4136-BABF-934B934018C9 Q35610581-A0ADFB1B-FD7C-4C87-8FB2-2E4508307D32 Q35819517-134BE333-1449-470C-AF3F-6864A19DE6FB Q35836909-101852AF-1DDD-43C2-AA0A-D74875A6EC5C Q36032452-AAF99F75-EC8A-49CD-A053-7BCB5251B9D4 Q36179080-ACD352C6-BC77-4E16-89A1-DDFA06A8921A Q36214193-03079BF8-74F5-47E8-AE4A-18BBABBDCE1D Q36233893-D77239E7-3A76-4B75-9DC2-3C6431FFB2BC Q36274292-4C9D426C-A7E3-4BF4-8800-1B2C07FC7928 Q36498128-4076C86C-B4A1-425F-A0B6-4B5E7C1B8210 Q36501059-6E452309-9A4D-4215-80C4-719AA8B36D04 Q36563578-4E5396D1-5328-4F4E-B61F-F7B3EC4CF554 Q36765341-4F4F0CBF-E771-477F-A55E-01C5AFFB8BAC Q36992455-AEE0D359-AEB1-430A-90D4-F055F6C2560F Q36997524-9FB6A51C-AC5E-4F06-8B25-0EF0F0CF9799 Q37017948-380AC5D7-05E5-4C70-815A-BA52DB0E1078 Q37028708-9E906ACC-F2B8-4F22-90C8-CD78176C3987 Q37051421-DE3578E5-6E34-4E1E-89E6-3EEBA05FC667 Q37123127-6A2033C7-D696-4C0A-829D-791008A35045 Q37166239-8436BE55-555D-4246-B351-820D51F4807E Q37321593-A1E5A254-8BD6-47E3-B273-6EA74D1BB6B0 Q37337359-AEA8F97E-15D3-44D5-9F5C-176C33F7D271 Q37687093-D8010F2C-3904-4BB6-B74F-CAB3ECEFCD42 Q38388784-AC97BB3F-270F-4956-977F-280F5F145718 Q38465850-F027CB92-AEAE-4BA0-8CBC-1EC973D4E096

P2860

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

http://www.wikidata.org/entity/Q27853093

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

@ast

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

@en

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

@nl

type

label

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

@ast

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

@en

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

@nl

altLabel

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

@en

prefLabel

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

@ast

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

@en

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

@nl

P1433

Q27853093-45305455-77F3-4FA6-B19A-21BAF9BA35C4

P1476

Q27853093-AC5D5C58-2AAC-403D-824F-533052BA47CA

P2093

Q27853093-06382F3D-1F59-410F-A60D-1DDFD714706C

Q27853093-0E32F05E-E159-4ADF-A063-BA607FBB98E1

Q27853093-2C40F4B6-F85F-4ED2-A86A-A37D3DD154B5

Q27853093-2D46B247-6C7A-420A-99CF-FD001D135950

Q27853093-401E524D-3035-42E6-B6C5-29B6DAA406E4

Q27853093-4653623F-9BAF-4D7A-8C84-03BD69DCAE04

Q27853093-47ABBC7D-0FD9-4E83-9733-94EC56F553EC

Q27853093-47E788F9-2462-4E1F-937C-FEB2A38D608E

Q27853093-4FD35FCA-4E3A-4EFE-B06B-EC0741B6EB1D

Q27853093-96B6F7ED-2582-4DE2-93EB-46280648C34B

P2860

Q27853093-06B5F467-CBC7-40CA-99A7-8CBE2CB3656A

Q27853093-1110A0EE-6575-4947-9785-17E1E895EF41

Q27853093-1D73CAF9-0F07-44E6-8B90-A49489745BA7

Q27853093-1FFB2185-510A-4BC9-900F-BDAD688B97FE

Q27853093-21F5CFF6-5D63-4975-BB3D-E75426CDF0B9

Q27853093-22C62423-C47B-4DAC-ACB3-11170F1E25ED

Q27853093-232C4298-A3BC-4BD6-83E5-C318663BC4C4

Q27853093-41A6B508-B87B-4493-9E17-E29311B066E2

Q27853093-5B9A0127-8BC9-4062-B0F1-17AE21DE3E1C

Q27853093-688A6751-6E2B-486C-B04A-596C9FBFCDA0

P2888

Q27853093-ADE30FC2-9064-4D6A-AEF6-44CD0B6BCBE8

P304

Q27853093-237BB8EB-FED0-4944-B56F-31CC93DF8005

P31

Q27853093-3B1176F6-28D3-4174-ACFB-18619CB7536A

P3181

Q27853093-5515E20D-BCE4-41DD-A9D2-A3C42AC7EBA2

P356

Q27853093-69750532-AF3F-4BFA-8EDB-64B49C7B33DF

P407

Q27853093-087FC361-902C-4A14-BFB2-22AB8E8C2076

P433

Q27853093-251689F2-8A5C-43D8-9CBB-671F2EAD108B

P478

Q27853093-DCFE90C1-25E5-42EC-96B4-25DBBE26AA13

P50

Q27853093-03FA3235-5FEA-4902-8DFF-14592E78E6D3

Q27853093-2C01BBDD-28D1-4838-A4E2-3C88CB2194EE

Q27853093-82C5C212-CFEC-4738-950E-FBD557D996BD

Q27853093-953074C6-CD18-4B50-9866-0463594DA123

Q27853093-A9347E57-EFE0-48C5-B618-B44E3E6F4EE6

Q27853093-B84A1ED3-6719-4D90-A0E5-B9062F897706

Q27853093-E69A8C2D-81FE-49E2-9A02-46F83875B50F

Q27853093-f2612a5c-4329-4a07-558d-fc3f2ee1a54d

P577

Q27853093-8FBEBA0E-7BA8-45FA-BC1A-94B310BF5364

P5875

Q27853093-C5F73A48-7CB5-4CA5-B374-2E345A264EA0

P6179

Q27853093-C109E016-9B64-44AD-985C-5D20AFB188B7

P698

Q27853093-85E84C29-7026-44A8-86EA-C35EB6223C39

P932

Q27853093-2F48D670-20FB-4413-A03B-438FA411FE6D

P3181

P356

P1433

P1476

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

@en

P2093

Adnan Derti

http://www.w3.org/2001/XMLSchema#string

Alan Huang

http://www.w3.org/2001/XMLSchema#string

Ashraf Thabet

http://www.w3.org/2001/XMLSchema#string

Cornelia Quadt

http://www.w3.org/2001/XMLSchema#string

David B Solit

http://www.w3.org/2001/XMLSchema#string

Dejan Juric

http://www.w3.org/2001/XMLSchema#string

Dennis Sgroi

http://www.w3.org/2001/XMLSchema#string

Gopa Iyer

http://www.w3.org/2001/XMLSchema#string

Haley Ellis

http://www.w3.org/2001/XMLSchema#string

Helen H Won

http://www.w3.org/2001/XMLSchema#string

P2860

Intratumor heterogeneity: evolution through space and time

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

Fast and accurate short read alignment with Burrows-Wheeler transform

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

The phosphoinositide 3-kinase pathway

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

High frequency of mutations of the PIK3CA gene in human cancers

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

P2888

P304

240-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

674769

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE13948

http://www.w3.org/2001/XMLSchema#string

P407

P433

7538

http://www.w3.org/2001/XMLSchema#string

P478

518

http://www.w3.org/2001/XMLSchema#string

P50

Benjamin J Ainscough

Malachi Griffith

Mari Mino-Kenudson

Benjamin J Ainscough

P577

2015-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268788243

http://www.w3.org/2001/XMLSchema#string

P6179

1040238174

http://www.w3.org/2001/XMLSchema#string

P698

25409150

http://www.w3.org/2001/XMLSchema#string

P932

4326538

http://www.w3.org/2001/XMLSchema#string